Literature DB >> 16534115

High-dose rituximab and anti-MAG-associated polyneuropathy.

S Renaud1, P Fuhr, M Gregor, K Schweikert, D Lorenz, C Daniels, G Deuschl, A Gratwohl, A J Steck.   

Abstract

Rituximab has been administered successfully in patients with polyneuropathy associated with antibodies to myelin-associated glycoprotein (anti-MAG). The authors present a follow-up study with high-dose rituximab. Increase of rituximab from 375 mg/m2 to a dose of 750 mg/m2 was well tolerated and led to clinical improvement in four of eight patients, along with improvement of nerve conduction velocities and a reduction of anti-MAG antibody titers.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16534115     DOI： 10.1212/01.wnl.0000201193.00382.b3

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  27 in total

1.  Increased serum levels of anti-ganglioside M1 auto-antibodies in autistic children: relation to the disease severity.

Authors:  Gehan A Mostafa; Laila Y Al-Ayadhi
Journal:  J Neuroinflammation       Date:  2011-04-25       Impact factor: 8.322

2.  Pathogenesis and treatment of immune-mediated neuropathies.

Authors:  Helmar C Lehmann; Gerd Meyer Zu Horste; Bernd C Kieseier; Hans-Peter Hartung
Journal:  Ther Adv Neurol Disord       Date:  2009-07       Impact factor: 6.570

3.  Practical considerations on the use of rituximab in autoimmune neurological disorders.

Authors:  Mixalis L Kosmidis; Marinos C Dalakas
Journal:  Ther Adv Neurol Disord       Date:  2010-03       Impact factor: 6.570

Review 4.  Update on therapy of chronic immune-mediated neuropathies.

Authors:  Chiara Briani; Dario Cocito; Marta Campagnolo; Pietro Emiliano Doneddu; Eduardo Nobile-Orazio
Journal:  Neurol Sci       Date:  2021-01-16       Impact factor: 3.307

Review 5.  Regulation of axonal regeneration following the central nervous system injury in adult mammalian.

Authors:  Ran Liu; Xi-Ping Chen; Lu-Yang Tao
Journal:  Neurosci Bull       Date:  2008-12       Impact factor: 5.203

6.  Treatment with rituximab in patients with polyneuropathy with anti-MAG antibodies.

Authors:  Emilien Delmont; P Y Jeandel; C Benaïm; E Rosenthal; J G Fuzibet; C Desnuelle
Journal:  J Neurol       Date:  2011-03-25       Impact factor: 4.849

Review 7.  Molecularly targeted therapies for dysimmune neuropathies.

Authors:  Andreas A Argyriou
Journal:  Mol Med       Date:  2009-05-05       Impact factor: 6.354

Review 8.  [Rituximab in treatment for neuroimmunological diseases].

Authors:  A Schröder; G Ellrichmann; G Chehab; M Schneider; R A Linker; R Gold
Journal:  Nervenarzt       Date:  2009-02       Impact factor: 1.214

9.  Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias.

Authors:  Aldo M Roccaro; Irene M Ghobrial; Simona Blotta; Steven P Treon; Michele Malagola; Kenneth C Anderson; Paul G Richardson; Domenico Russo
Journal:  Biologics       Date:  2008-09

10.  Anti-myelin-associated glycoprotein peripheral neuropathy as the only presentation of low grade lymphoma: a case report.

Authors:  Costantine Albany
Journal:  Cases J       Date:  2009-07-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.